

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claims 1-59 (Canceled)

Claim 60 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 353 nucleotides.

Claim 61 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in any of Figures 1, 3 or 4, wherein said polynucleotide has a maximum length of 586 nucleotides.

Claim 62 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 353 nucleotides.

Claim 63 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in any of the viral cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394, wherein said polynucleotide has a maximum length of 586 nucleotides.

Claim 64 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 353 nucleotides.

Claim 65 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 14, wherein said polynucleotide has a maximum length of 586 nucleotides.

Claim 66 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 353 nucleotides.

Claim 67 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 26, wherein said polynucleotide has a maximum length of 586 nucleotides.

Claim 68 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figures 57, wherein said polynucleotide has a maximum length of 353 nucleotides.

Claim 69 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 57, wherein said polynucleotide has a maximum length of 586 nucleotides.

Claim 70 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.

Claim 71 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 59 or the nucleotide sequence shown in Figure 62 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.

Claim 72 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 353 nucleotides.

Claim 73 (Previously Presented): A polynucleotide comprising a contiguous sequence that is identical to a sequence of at least 12 contiguous nucleotides shown in either strand of the nucleotide sequence in Figure 72 or the nucleotide sequence shown in Figure 89 or the complement thereof, wherein said polynucleotide has a maximum length of 586 nucleotides.

Claims 74-75 (Canceled)

Claim 76 (Previously Presented): A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 15 nucleotides.

Claim 77 (Previously Presented): A polynucleotide according to any one of claims 60-73, wherein said contiguous sequence is at least 20 nucleotides.

Claim 78 (Previously Presented): A polynucleotide according to any of claims 60-73 wherein said polynucleotide has a maximum length of 161 nucleotides.

Claims 79-80 (Canceled)

Claim 81 (Previously Presented): A polynucleotide according to claim 76 wherein said polynucleotide has a maximum length of 161 nucleotides.

Claim 82 (Previously Presented): A polynucleotide according to claim 77 wherein said polynucleotide has a maximum length of 161 nucleotides.

Claim 83 (Previously Presented): A polynucleotide according to any of claims 60-73 wherein said polynucleotide has a maximum length of 108 nucleotides.

Claims 84-85 (Canceled)

Claim 86 (Previously Presented): A polynucleotide according to claim 76 wherein said polynucleotide has a maximum length of 108 nucleotides.

Claim 87 (Previously Presented): A polynucleotide according to claim 77 wherein said polynucleotide has a maximum length of 108 nucleotides

Claim 88 (Previously Presented): A polynucleotide according to any of claims 60-73 wherein said polynucleotide is single stranded.

Claims 89-90 (Canceled)

Claim 91 (Previously Presented): A polynucleotide according to claim 76 wherein said polynucleotide is single stranded.

Claim 92 (Previously Presented): A polynucleotide according to claim 77 wherein said polynucleotide is single stranded.

Claim 93 (Previously Presented): A polynucleotide according to claim 78 wherein said polynucleotide is single stranded.

Claims 94-95 (Canceled)

Claim 96 (Previously Presented): A polynucleotide according to claim 81 wherein said polynucleotide is single stranded.

Claim 97 (Previously Presented): A polynucleotide according to claim 82 wherein said polynucleotide is single stranded.

Claim 98 (Previously Presented): A polynucleotide according to claim 83 wherein said polynucleotide is single stranded.

Claims 99-100 (Canceled)

Claim 101 (Previously Presented): A polynucleotide according to claim 86 wherein said polynucleotide is single stranded.

Claim 102 (Previously Presented): A polynucleotide according to claim 87 wherein said polynucleotide is single stranded.

Claim 103 (Previously Presented): A polynucleotide according to any of claims 60-73 wherein said polynucleotide is DNA.

Claims 104-105 (Canceled)

Claim 106 (Previously Presented): A polynucleotide according to claim 76 wherein said polynucleotide is DNA.

Claim 107 (Previously Presented): A polynucleotide according to claim 77 wherein said polynucleotide is DNA.

Claim 108 (Previously Presented): A polynucleotide according to claim 78 wherein said polynucleotide is DNA.

Claims 109-110 (Canceled)

Claim 111 (Previously Presented): A polynucleotide according to claim 81 wherein said polynucleotide is DNA.

Claim 112 (Previously Presented): A polynucleotide according to claim 82 wherein said polynucleotide is DNA.

Claim 113 (Previously Presented): A polynucleotide according to claim 83 wherein said polynucleotide is DNA.

Claims 114-115 (Canceled)

Claim 116 (Previously Presented): A polynucleotide according to claim 86 wherein said polynucleotide is DNA.

Claim 117 (Previously Presented): A polynucleotide according to claim 87 wherein said polynucleotide is DNA.

Claim 118 (Previously Presented): A polynucleotide according to claim 88 wherein said polynucleotide is DNA.

Claims 119-120 (Canceled)

Claim 121 (Previously Presented): A polynucleotide according to claim 91 wherein said polynucleotide is DNA.

Claim 122 (Previously Presented): A polynucleotide according to claim 92 wherein said polynucleotide is DNA.

Claim 123 (Previously Presented): A polynucleotide according to claim 93 wherein said polynucleotide is DNA.

Claims 124-125 (Canceled)

Claim 126 (Previously Presented): A polynucleotide according to claim 96 wherein said polynucleotide is DNA.

Claim 127 (Previously Presented): A polynucleotide according to claim 97 wherein said polynucleotide is DNA.

Claim 128 (Previously Presented): A polynucleotide according to claim 98 wherein said polynucleotide is DNA.

Claims 129-130 (Canceled)

Claim 131 (Previously Presented): A polynucleotide according to claim 101 wherein said polynucleotide is DNA.

Claim 132 (Previously Presented): A polynucleotide according to claim 102 wherein said polynucleotide is DNA.

Claim 133 (Previously Presented): A polynucleotide according to any of claims 60-73 wherein said polynucleotide is labeled.

Claims 134-135 (Canceled)

Claim 136 (Previously Presented): A polynucleotide according to claim 76 wherein said polynucleotide is labeled.

Claim 137 (Previously Presented): A polynucleotide according to claim 77 wherein said polynucleotide is labeled.

Claim 138 (Previously Presented): A polynucleotide according to claim 78 wherein said polynucleotide is labeled.

Claims 139-140 (Canceled)

Claim 141 (Previously Presented): A polynucleotide according to claim 81 wherein said polynucleotide is labeled.

Claim 142 (Previously Presented): A polynucleotide according to claim 82 wherein said polynucleotide is labeled.

Claim 143 (Previously Presented): A polynucleotide according to claim 83 wherein said polynucleotide is labeled.

Claims 144-145 (Canceled)

Claim 146 (Previously Presented): A polynucleotide according to claim 86 wherein said polynucleotide is labeled.

Claim 147 (Previously Presented): A polynucleotide according to claim 87 wherein said polynucleotide is labeled.

Claim 148 (Previously Presented): A polynucleotide according to claim 88 wherein said polynucleotide is labeled.

Claims 149-150 (Canceled)

Claim 151 (Previously Presented): A polynucleotide according to claim 91 wherein said polynucleotide is labeled.

Claim 152 (Previously Presented): A polynucleotide according to claim 92 wherein said polynucleotide is labeled.

Claim 153 (Previously Presented): A polynucleotide according to claim 93 wherein said polynucleotide is labeled.

Claims 154-155 (Canceled)

Claim 156 (Previously Presented): A polynucleotide according to claim 96 wherein said polynucleotide is labeled.

Claim 157 (Previously Presented): A polynucleotide according to claim 97 wherein said polynucleotide is labeled.

Claim 158 (Previously Presented): A polynucleotide according to claim 98 wherein said polynucleotide is labeled.

Claims 159-160 (Canceled)

Claim 161 (Previously Presented): A polynucleotide according to claim 101 wherein said polynucleotide is labeled.

Claim 162 (Previously Presented): A polynucleotide according to claim 102 wherein said polynucleotide is labeled.

Claim 163 (Previously Presented): A polynucleotide according to claim 103 wherein said polynucleotide is labeled.

Claims 164-165 (Canceled)

Claim 166 (Previously Presented): A polynucleotide according to claim 106 wherein said polynucleotide is labeled.

Claim 167 (Previously Presented): A polynucleotide according to claim 107 wherein said polynucleotide is labeled.

Claim 168 (Previously Presented): A polynucleotide according to claim 108 wherein said polynucleotide is labeled.

Claims 169-170 (Canceled)

Claim 171 (Previously Presented): A polynucleotide according to claim 111 wherein said polynucleotide is labeled.

Claim 172 (Previously Presented): A polynucleotide according to claim 112 wherein said polynucleotide is labeled.

Claim 173 (Previously Presented): A polynucleotide according to claim 113 wherein said polynucleotide is labeled.

Claims 174-175 (Canceled)

Claim 176 (Previously Presented): A polynucleotide according to claim 116 wherein said polynucleotide is labeled.

Claim 177 (Previously Presented): A polynucleotide according to claim 117 wherein said polynucleotide is labeled.

Claim 178 (Previously Presented): A polynucleotide according to claim 118 wherein said polynucleotide is labeled.

Claims 179-180 (Canceled)

Claim 181 (Previously Presented): A polynucleotide according to claim 121 wherein said polynucleotide is labeled.

Claim 182 (Previously Presented): A polynucleotide according to claim 122 wherein said polynucleotide is labeled.

Claim 183 (Previously Presented): A polynucleotide according to claim 123 wherein said polynucleotide is labeled.

Claims 184-185 (Canceled)

Claim 186 (Previously Presented): A polynucleotide according to claim 126 wherein said polynucleotide is labeled.

Claim 187 (Previously Presented): A polynucleotide according to claim 127 wherein said polynucleotide is labeled.

Claim 188 (Previously Presented): A polynucleotide according to claim 128 wherein said polynucleotide is labeled.

Claims 189-190 (Canceled)

Claim 191 (Previously Presented): A polynucleotide according to claim 131 wherein said polynucleotide is labeled.

Claim 192 (Previously Presented): A polynucleotide according to claim 132 wherein said polynucleotide is labeled.

Claim 193 (Previously Presented): A polynucleotide according to any of claims 60-73 wherein said polynucleotide is RNA.

Claims 194-195 (Canceled)

Claim 196 (Previously Presented): A polynucleotide according to claim 76 wherein said polynucleotide is RNA.

Claim 197 (Previously Presented): A polynucleotide according to claim 77 wherein said polynucleotide is RNA.

Claim 198 (Previously Presented): A polynucleotide according to claim 78 wherein said polynucleotide is RNA.

Claims 199-200 (Canceled)

Claim 201 (Previously Presented): A polynucleotide according to claim 81 wherein said polynucleotide is RNA.

Claim 202 (Previously Presented): A polynucleotide according to claim 82 wherein said polynucleotide is RNA.

Claim 203 (Previously Presented): A polynucleotide according to claim 83 wherein said polynucleotide is RNA.

Claims 204-205 (Canceled)

Claim 206 (Previously Presented): A polynucleotide according to claim 86 wherein said polynucleotide is RNA.

Claim 207 (Previously Presented): A polynucleotide according to claim 87 wherein said polynucleotide is RNA.

Claim 208 (Previously Presented): A polynucleotide according to claim 88 wherein said polynucleotide is RNA.

Claims 209-210 (Canceled)

Claim 211 (Previously Presented): A polynucleotide according to claim 91 wherein said polynucleotide is RNA.

Claim 212 (Previously Presented): A polynucleotide according to claim 92 wherein said polynucleotide is RNA.

Claim 213 (Previously Presented): A polynucleotide according to claim 93 wherein said polynucleotide is RNA.

Claims 214-215 (Canceled)

Claim 216 (Previously Presented): A polynucleotide according to claim 96 wherein said polynucleotide is RNA.

Claim 217 (Previously Presented): A polynucleotide according to claim 97 wherein said polynucleotide is RNA.

Claim 218 (Previously Presented): A polynucleotide according to claim 98 wherein said polynucleotide is RNA.

Claims 219-220 (Canceled)

Claim 221 (Previously Presented): A polynucleotide according to claim 101 wherein said polynucleotide is RNA.

Claim 222 (Previously Presented): A polynucleotide according to claim 102 wherein said polynucleotide is RNA.

Claim 223 (Previously Presented): A polynucleotide according to claim 193 wherein said polynucleotide is labeled.

Claims 224-225 (Canceled)

Claim 226 (Previously Presented): A polynucleotide according to claim 196 wherein said polynucleotide is labeled.

Claim 227 (Previously Presented): A polynucleotide according to claim 197 wherein said polynucleotide is labeled.

Claim 228 (Previously Presented): A polynucleotide according to claim 198 wherein said polynucleotide is labeled.

Claims 229-230 (Canceled)

Claim 231 (Previously Presented): A polynucleotide according to claim 201 wherein said polynucleotide is labeled.

Claim 232 (Previously Presented): A polynucleotide according to claim 202 wherein said polynucleotide is labeled.

Claim 233 (Previously Presented): A polynucleotide according to claim 203 wherein said polynucleotide is labeled.

Claims 234-235 (Canceled)

Claim 236 (Previously Presented): A polynucleotide according to claim 206 wherein said polynucleotide is labeled.

Claim 237 (Previously Presented): A polynucleotide according to claim 207 wherein said polynucleotide is labeled.

Claim 238 (Previously Presented): A polynucleotide according to claim 208 wherein said polynucleotide is labeled.

Claims 239-240 (Canceled)

Claim 241 (Previously Presented): A polynucleotide according to claim 211 wherein said polynucleotide is labeled.

Claim 242 (Previously Presented): A polynucleotide according to claim 212 wherein said polynucleotide is labeled.

Claim 243 (Previously Presented): A polynucleotide according to claim 213 wherein said polynucleotide is labeled.

Claims 244-245 (Canceled)

Claim 246 (Previously Presented): A polynucleotide according to claim 216 wherein said polynucleotide is labeled.

Claim 247 (Previously Presented): A polynucleotide according to claim 217 wherein said polynucleotide is labeled.

Claim 248 (Previously Presented): A polynucleotide according to claim 218 wherein said polynucleotide is labeled.

Claims 249-250 (Canceled)

Claim 251 (Previously Presented): A polynucleotide according to claim 221 wherein said polynucleotide is labeled.

Claim 252 (Previously Presented): A polynucleotide according to any of claims 60-73 wherein said polynucleotide is an oligonucleotide.

Claims 253-254 (Canceled)

Claim 255 (Previously Presented): A polynucleotide according to claim 76 wherein said polynucleotide is an oligonucleotide.

Claim 256 (Previously Presented): A polynucleotide according to claim 77 wherein said polynucleotide is an oligonucleotide.

Claim 257 (Previously Presented): A polynucleotide according to claim 78 wherein said polynucleotide is an oligonucleotide.

Claims 258-259 (Canceled)

Claim 260 (Previously Presented): A polynucleotide according to claim 81 wherein said polynucleotide is an oligonucleotide.

Claim 261 (Previously Presented): A polynucleotide according to claim 82 wherein said polynucleotide is an oligonucleotide.

Claim 262 (Previously Presented): A polynucleotide according to claim 83 wherein said polynucleotide is an oligonucleotide.

Claims 263-264 (Canceled)

Claim 265 (Previously Presented): A polynucleotide according to claim 86 wherein said polynucleotide is an oligonucleotide.

Claim 266 (Previously Presented): A polynucleotide according to claim 87 wherein said polynucleotide is an oligonucleotide.

Claim 267 (Previously Presented): A polynucleotide according to claim 222 wherein said polynucleotide is labeled.

Claim 268 (Previously Presented): An oligonucleotide according to claim 252 wherein said oligonucleotide is labeled.

Claims 269-270 (Canceled)

Claim 271 (Previously Presented): An oligonucleotide according to claim 255 wherein said oligonucleotide is labeled.

Claim 272 (Previously Presented): An oligonucleotide according to claim 256 wherein said oligonucleotide is labeled.

Claim 273 (Previously Presented): An oligonucleotide according to claim 257 wherein said oligonucleotide is labeled.

Claims 274-275 (Canceled)

Claim 276 (Previously Presented): An oligonucleotide according to claim 260 wherein said oligonucleotide is labeled.

Claim 277 (Previously Presented): An oligonucleotide according to claim 261 wherein said oligonucleotide is labeled.

Claim 278 (Previously Presented): An oligonucleotide according to claim 262 wherein said oligonucleotide is labeled.

Claims 279-280 (Canceled)

Claim 281 (Previously Presented): An oligonucleotide according to claim 265 wherein said oligonucleotide is labeled.

Claim 282 (Previously Presented): An oligonucleotide according to claim 266 wherein said oligonucleotide is labeled.

Claim 283 (Previously Presented): A polynucleotide according to claim 267 wherein said polynucleotide is an oligonucleotide.

Claim 284 (Previously Presented): A composition comprising the polynucleotide of any of claims 60-73 wherein said polynucleotide is substantially isolated.

Claims 285-286 (Canceled)

Claim 287 (Previously Presented): A composition comprising the polynucleotide of claim 76 wherein said polynucleotide is substantially isolated.

Claim 288 (Previously Presented): A composition comprising the polynucleotide of claim 77 wherein said polynucleotide is substantially isolated.

Claim 289 (Previously Presented): A composition comprising the polynucleotide of claim 78 wherein said polynucleotide is substantially isolated.

Claims 290-291 (Canceled)

Claim 292 (Previously Presented): A composition comprising the polynucleotide of claim 81 wherein said polynucleotide is substantially isolated.

Claim 293 (Previously Presented): A composition comprising the polynucleotide of claim 82 wherein said polynucleotide is substantially isolated.

Claim 294 (Previously Presented): A composition comprising the polynucleotide of claim 83 wherein said polynucleotide is substantially isolated.

Claims 295-296 (Canceled)

Claim 297 (Previously Presented): A composition comprising the polynucleotide of claim 86 wherein said polynucleotide is substantially isolated.

Claim 298 (Previously Presented): A composition comprising the polynucleotide of claim 87 wherein said polynucleotide is substantially isolated.

Claim 299 (Previously Presented): A composition comprising the polynucleotide of claim 88 wherein said polynucleotide is substantially isolated.

Claims 300-301 (Canceled)

Claim 302 (Previously Presented): A composition comprising the polynucleotide of claim 91 wherein said polynucleotide is substantially isolated.

Claim 303 (Previously Presented): A composition comprising the polynucleotide of claim 92 wherein said polynucleotide is substantially isolated.

Claim 304 (Previously Presented): A composition comprising the polynucleotide of claim 93 wherein said polynucleotide is substantially isolated.

Claims 305-306 (Canceled)

Claim 307 (Previously Presented): A composition comprising the polynucleotide of claim 96 wherein said polynucleotide is substantially isolated.

Claim 308 (Previously Presented): A composition comprising the polynucleotide of claim 97 wherein said polynucleotide is substantially isolated.

Claim 309 (Previously Presented): A composition comprising the polynucleotide of claim 98 wherein said polynucleotide is substantially isolated.

Claims 310-311 (Canceled)

Claim 312 (Previously Presented): A composition comprising the polynucleotide of claim 101 wherein said polynucleotide is substantially isolated.

Claim 313 (Previously Presented): A composition comprising the polynucleotide of claim 102 wherein said polynucleotide is substantially isolated.

Claim 314 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of any of claims 60-73 in a suitable package.

Claims 315-316 (Canceled)

Claim 317 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 76 in a suitable package.

Claim 318 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 77 in a suitable package.

Claim 319 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 78 in a suitable package.

Claims 320-321 (Canceled)

Claim 322 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 81 in a suitable package.

Claim 323 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 82 in a suitable package.

Claim 324 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 83 in a suitable package.

Claims 325-326 (Canceled)

Claim 327 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 86 in a suitable package.

Claim 328 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 87 in a suitable package.

Claim 329 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 88 in a suitable package.

Claims 330-331 (Canceled)

Claim 332 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 113 in a suitable package.

Claim 333 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 117 in a suitable package.

Claim 334 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 133 in a suitable package.

Claim 335 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 193 in a suitable package.

Claim 336 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 223 in a suitable package.

Claim 337 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 252 in a suitable package.

Claim 338 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 284 in a suitable package.

Claim 339 (Previously Presented): A kit for analyzing samples for the presence of HCV comprising at least one polynucleotide of claim 268 in a suitable package.

Claim 340 (Previously Presented): A polynucleotide of any of claims 60-73 wherein said polynucleotide encodes a polypeptide having a sequence comprising at least 10 contiguous amino acids from an HCV1 polyprotein.

Claim 341 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 3.

Claim 342 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 62A.

Claim 343 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a contiguous sequence of at least 15 nucleotides fully complementary to either strand of Figure 89.

Claim 344 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

Claim 345 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-11 cDNA library deposited as ATCC No. 40394.

Claim 346 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 89.

Claim 347 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides found in either strand of Figure 14.

Claim 348 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that comprise a polynucleotide that hybridizes under stringent conditions to a contiguous sequence of at least 15 nucleotides from either strand of Figure 58.

Claim 349 (Previously Presented): A method according to any of claims 344-348 wherein said selected samples comprise said polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said polynucleotide and said contiguous sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

Claim 350 (Canceled)

Claim 351 (Previously Presented): A method according to claim 349 wherein said polynucleotide is detectable in a PCR assay.

Claim 352 (Previously Presented): A method according to claim 349 wherein said biological samples are blood.

Claim 353 (Canceled)

Claim 354 (Previously Presented): A method according to claim 351 wherein said biological samples are blood.

Claim 355 (Previously Presented): A method according to claim 349 wherein said biological samples are plasma.

Claim 356 (Canceled)

Claim 357 (Previously Presented): A method according to claim 351 wherein said biological samples are plasma.

Claim 358 (Previously Presented): A method according to claim 349 wherein said biological samples are sera.

Claim 359 (Canceled)

Claim 360 (Previously Presented): A method according to claim 351 wherein said biological samples are sera.

Claim 361 (Previously Presented): A method according to claim 352 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 362 (Previously Presented): A method according to claim 355 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 363 (Previously Presented): A method according to claim 352 further comprising preparing polyclonal antibodies with selected biological samples.

Claim 364 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

Claim 365 (Previously Presented): A method of selecting biological samples from a supply of human biological samples comprising selecting from said supply those samples that contain a detectable polynucleotide comprising a sequence that is fully complementary to a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt- 11 cDNA library deposited as ATCC No. 40394.

Claim 366 (Previously Presented): A method according to claim 352 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 367 (Canceled)

Claim 368 (Previously Presented): A method according to claim 354 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 369 (Previously Presented): A method according to claim 355 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 370 (Canceled)

Claim 371 (Previously Presented): A method according to claim 357 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 372 (Previously Presented): A method according to claim 358 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 373 (Canceled)

Claim 374 (Previously Presented): A method according to claim 360 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 375 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

Claim 376 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second

polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from the genome of a hepatitis C virus genome or the complement thereof.

Claim 377 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-ll cDNA library deposited as ATCC No. 40394.

Claim 378 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides from either strand of at least one of the HCV cDNA inserts in a lambda gt-ll cDNA library deposited as ATCC No. 40394.

Claim 379 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

Claim 380 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in Figure 89, or the complement thereof.

Claim 381 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which comprise a first

polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either strand of Figure 58.

Claim 382 (Previously Presented): A method of selecting samples from a supply of human biological samples comprising selecting from said supply those samples which do not comprise a first polynucleotide that is capable of hybridizing under stringent conditions to a second polynucleotide that comprises a contiguous sequence of at least 15 nucleotides found in either stand of Figure 58.

Claim 383 (Previously Presented): A method according to any of claims 375, 377, 379, 381 wherein said selected samples comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence of nucleotides and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

Claim 384 (Previously Presented): A method according to any of claims 376, 378, 380, 382 wherein said selected samples do not comprise said first polynucleotide and said stringent conditions permit the formation of a stable hybrid duplex between said first polynucleotide and said contiguous sequence and do not permit the formation of a stable duplex between said contiguous sequence and the genomes of Hepatitis B or Hepatitis A viruses.

Claim 385 (Previously Presented): A method according to claim 383, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

Claim 386 (Previously Presented): A method according to claim 384, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

Claim 387 (Previously Presented): A method according to claim 383 wherein said first polynucleotide is detectable in a PCR assay.

Claim 388 (Previously Presented): A method according to 385, wherein said first polynucleotide is detectable in a PCR assay.

Claim 389 (Previously Presented): A method according to claim 384 wherein said first polynucleotide is not detectable in a PCR assay.

Claim 390 (Previously Presented): A method according to claim 386 wherein said first polynucleotide is not detectable in a PCR assay.

Claim 391 (Previously Presented): A method according to any of claims 375-382 wherein said biological samples are blood.

Claim 392 (Previously Presented): A method according to claim 383 wherein said biological samples are blood.

Claim 393 (Previously Presented): A method according to claim 384 wherein said biological samples are blood.

Claim 394 (Previously Presented): A method according to claim 385 wherein said biological samples are blood.

Claim 395 (Previously Presented): A method according to claim 386 wherein said biological samples are blood.

Claim 396 (Previously Presented): A method according to claim 387 wherein said biological samples are blood.

Claim 397 (Previously Presented): A method according to claim 388 wherein said biological samples are blood.

Claim 398 (Previously Presented): A method according to claim 389 wherein said biological samples are blood.

Claim 399 (Previously Presented): A method according to claim 390 wherein said biological samples are blood.

Claim 400 (Previously Presented): A method according to any of claims 375-382 wherein said biological samples are plasma.

Claim 401 (Previously Presented): A method according to claim 383 wherein said biological samples are plasma.

Claim 402 (Previously Presented): A method according to claim 384 wherein said biological samples are plasma.

Claim 403 (Previously Presented): A method according to claim 385 wherein said biological samples are plasma.

Claim 404 (Previously Presented): A method according to claim 386 wherein said biological samples are plasma.

Claim 405 (Previously Presented): A method according to claim 387 wherein said biological samples are plasma.

Claim 406 (Previously Presented): A method according to claim 388 wherein said biological samples are plasma.

Claim 407 (Previously Presented): A method according to claim 389 wherein said biological samples are plasma.

Claim 408 (Previously Presented): A method according to claim 390 wherein said biological samples are plasma.

Claim 409 (Previously Presented): A method according to any of claims 375-382 wherein said biological samples are sera.

Claim 410 (Previously Presented): A method according to claim 383 wherein said biological samples are sera.

Claim 411 (Previously Presented): A method according to claim 384 wherein said biological samples are sera.

Claim 412 (Previously Presented): A method according to claim 385 wherein said biological samples are sera.

Claim 413 (Previously Presented): A method according to claim 386 wherein said biological samples are sera.

Claim 414 (Previously Presented): A method according to claim 387 wherein said biological samples are sera.

Claim 415 (Previously Presented): A method according to claim 388 wherein said biological samples are sera.

Claim 416 (Previously Presented): A method according to claim 389 wherein said biological samples are sera.

Claim 417 (Previously Presented): A method according to claim 390 wherein said biological samples are sera.

Claim 418 (Previously Presented): A method according to any of claims 375, 377, 379 or 381 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 419 (Previously Presented): A method according to claim 383 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 420 (Previously Presented): A method according to claim 385 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 421 (Previously Presented): A method according to claim 387 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 422 (Previously Presented): A method according to claim 388 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 423 (Previously Presented): A method according to any of claims 376, 378, 380 or 382 further comprising employing biological samples that are selected for a preparation of blood-related products.

Claim 424 (Previously Presented): A method according to claim 384 further comprising employing biological samples that are selected for a preparation of blood-related products.

Claim 425 (Previously Presented): A method according to claim 386 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 426 (Previously Presented): A method according to claim 389 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 427 (Previously Presented): A method according to claim 390 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 428 (Previously Presented): A method according to any of claims 376, 378, 380 or 382 wherein said selected samples are supply samples for preparation of blood products.

Claim 429 (Previously Presented): A method according to claim 384 wherein said selected samples are supply sample for preparation of blood products.

Claim 430 (Previously Presented): A method according to claim 386 wherein said selected samples are supply sample for preparation of blood products.

Claim 431 (Previously Presented): A method according to claim 389 wherein said selected samples are supply sample for preparation of blood products.

Claim 432 (Previously Presented): A method according to claim 390 wherein said selected samples are supply sample for preparation of blood products.

Claim 433 (Previously Presented): A method according to any of claims 375, 377, 379 or 381 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 434 (Previously Presented): A method according to claim 383 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 435 (Previously Presented): A method according to claim 385 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 436 (Previously Presented): A method according to claim 387 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 437 (Previously Presented): A method according to claim 388 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 438 (Previously Presented): A method according to any of claims 341-348, 364 or 365 wherein said polynucleotide is detectable in a PCR assay.

Claim 439 (Previously Presented): A method according to claim 438 wherein said biological samples are blood.

Claim 440 (Previously Presented): A method according to claim 438 wherein said biological samples are plasma.

Claim 441 (Previously Presented): A method according to claim 438 wherein said biological samples are sera.

Claim 442 (Previously Presented): A method according to claim 439 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 443 (Previously Presented): A method according to claim 440 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 444 (Previously Presented): A method according to claim 441 wherein the selecting is to identify an HCV positive sample for removal from the supply.

Claim 445 (Previously Presented): A method according to claims 344-348, wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

Claim 446 (Previously Presented): A method according to claim 349 wherein said stringent conditions include using 50% (w/v) formamide and washing in 5xSSC, 0.1 % SDS at 55 DC.

Claim 447 (Previously Presented): A method according to claim 445 wherein said polynucleotide is detectable in a PCR assay.

Claim 448 (Previously Presented): A method according to claim 446 wherein said polynucleotide is detectable in a PCR assay.

Claim 449 (Previously Presented): A method according to claim 445 wherein said biological samples are blood.

Claim 450 (Previously Presented): A method according to claim 446 wherein said biological samples are blood.

Claim 451 (Previously Presented): A method according to claim 445 wherein said biological samples are plasma.

Claim 452 (Previously Presented): A method according to claim 446 wherein said biological samples are plasma.

Claim 453 (Previously Presented): A method according to claim 445 wherein said biological samples are sera.

Claim 454 (Previously Presented): A method according to claim 446 wherein said biological samples are sera.

Claim 455 (Previously Presented): A method according to claim 447 wherein said biological samples are blood.

Claim 456 (Previously Presented): A method according to claim 448 wherein said biological samples are blood.

Claim 457 (Previously Presented): A method according to claim 447 wherein said biological samples are sera.

Claim 458 (Previously Presented): A method according to claim 448 wherein said biological samples are sera.

Claim 459 (Previously Presented): A method according to claim 447 wherein said biological samples are plasma.

Claim 460 (Previously Presented): A method according to claim 448 wherein said biological samples are plasma.

Claim 461 (Previously Presented): A method according to claim 445 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 462 (Previously Presented): A method according to claim 446 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 463 (Previously Presented): A method according to claim 447 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 464 (Previously Presented): A method according to claim 448 further comprising employing biological samples that are not selected for a preparation of blood-related products.

Claim 465 (Previously Presented): A method according to claim 445 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 466 (Previously Presented): A method according to claim 446 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 467 (Previously Presented): A method according to claim 447 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 468 (Previously Presented): A method according to claim 448 wherein said samples that are not selected are supply samples for preparation of blood products.

Claim 469 (Previously Presented): A method according to claim 358 further comprising employing biological samples that are not selected for a preparation of blood-related products.